Investment Analysts’ Recent Ratings Updates for Enovis (ENOV)

A number of research firms have changed their ratings and price targets for Enovis (NYSE: ENOV):

• 3/14/2026 – Enovis was upgraded by Wall Street Zen from “hold” to “buy”.
• 3/4/2026 – Enovis was upgraded by Zacks Research from “hold” to “strong-buy”.
• 2/26/2026 – Enovis had its price target raised by Needham & Company LLC from $49.00 to $52.00. They now have a “buy” rating on the stock.
• 2/26/2026 – Enovis had its price target raised by BTIG Research from $41.00 to $43.00. They now have a “buy” rating on the stock.

Insider Transactions at Enovis

In other news, insider Oliver Engert acquired 1,000 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were purchased at an average price of $25.50 per share, for a total transaction of $25,500.00. Following the completion of the transaction, the insider owned 43,640 shares of the company’s stock, valued at $1,112,820. The trade was a 2.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have acquired 5,000 shares of company stock valued at $121,983. 2.70% of the stock is owned by company insiders.

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.